# A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)

> **NCT02630368** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Institut Bergonié** · enrollment: 197 (estimated)

## Conditions studied

- Solid Tumors
- Soft-tissue Sarcoma
- Breast Cancer

## Interventions

- **DRUG:** Cyclophosphamide and JX-594 dose escalation
- **DRUG:** Cyclophosphamide and JX-594
- **DRUG:** Cyclophosphamide
- **DRUG:** Avelumab and JX-594 and Cyclophosphamide

## Key facts

- **NCT ID:** NCT02630368
- **Lead sponsor:** Institut Bergonié
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-09-18
- **Primary completion:** 2023-05
- **Final completion:** 2024-11
- **Target enrollment:** 197 (ESTIMATED)
- **Last updated:** 2022-02-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02630368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02630368, "A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02630368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*